Novel gemcitabine-containing triplets in the management of urothelial cancer

Maha Hussain*, Ulka Vaishampayan, David C. Smith

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Chemotherapy has been the cornerstone of treatment of advanced urothelial cancer. For a decade, the combination regimen of methotrexate/vinblastine/doxorubicin/cisplatin has been considered the standard for these patients. The need for improved efficacy and reduced toxicity of a predominantly palliative therapy has propelled efforts for new drug development. Of the newly identified agents with documented activity, both gemcitabine and paclitaxel have been evaluated with a platinum and have been incorporated into multiagent chemotherapy combinations. Phase II data from two gemcitabine-based triplets are currently available. Combination gemcitabine/paclitaxel/cisplatin and gemcitabine/paclitaxel/carboplatin have high levels of activity with overall and complete response rates of 76% and 26%, respectively, for the former and 68% and 32%, respectively, for the latter combination. The role of gemcitabine-based multiagent combinations compared with standard therapy awaits evaluation in prospectively randomized trials.

Original languageEnglish (US)
Pages (from-to)20-24
Number of pages5
JournalSeminars in Oncology
Issue number1 SUPPL. 3
StatePublished - 2002

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Novel gemcitabine-containing triplets in the management of urothelial cancer'. Together they form a unique fingerprint.

Cite this